Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance.
Elina A PietiläJordi Gonzalez-MolinaLidia Moyano-GalceranSanaz JamalzadehKaiyang ZhangLaura LehtinenS Pauliina TurunenTomás A MartinsOkan GultekinTarja LamminenKatja KaipioUlrika JoneborgJohanna HynninenSakari HietanenSeija GrénmanRainer LehtonenSampsa HautaniemiOlli CarpénJoseph W CarlsonKaisa LehtiPublished in: Nature communications (2021)
Due to its dynamic nature, the evolution of cancer cell-extracellular matrix (ECM) crosstalk, critically affecting metastasis and treatment resistance, remains elusive. Our results show that platinum-chemotherapy itself enhances resistance by progressively changing the cancer cell-intrinsic adhesion signaling and cell-surrounding ECM. Examining ovarian high-grade serous carcinoma (HGSC) transcriptome and histology, we describe the fibrotic ECM heterogeneity at primary tumors and distinct metastatic sites, prior and after chemotherapy. Using cell models from systematic ECM screen to collagen-based 2D and 3D cultures, we demonstrate that both specific ECM substrates and stiffness increase resistance to platinum-mediated, apoptosis-inducing DNA damage via FAK and β1 integrin-pMLC-YAP signaling. Among such substrates around metastatic HGSCs, COL6 was upregulated by chemotherapy and enhanced the resistance of relapse, but not treatment-naïve, HGSC organoids. These results identify matrix adhesion as an adaptive response, driving HGSC aggressiveness via co-evolving ECM composition and sensing, suggesting stromal and tumor strategies for ECM pathway targeting.
Keyphrases
- drug delivery
- extracellular matrix
- high grade
- single cell
- dna damage
- squamous cell carcinoma
- small cell lung cancer
- locally advanced
- cell therapy
- gene expression
- rna seq
- bone marrow
- radiation therapy
- mesenchymal stem cells
- systemic sclerosis
- combination therapy
- pseudomonas aeruginosa
- dna methylation
- replacement therapy